Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Legal Considerations and FDA Regulations for PRP, Exosomes, and Stem Cells
Description
The speaker reviews the legal and regulatory issues surrounding PRP, exosomes, and stem cells, emphasizing that PRP is a lucrative market but is FDA-cleared, not FDA-approved, and only through the 510(k) pathway for specific preparation kits. The FDA regulates the kits rather than the blood itself, and any deviation from minimal manipulation, such as adding calcium or other agents, can remove a product from the cleared category. The talk stresses that using PRP off-label for hair or skin is common but shifts liability to the clinician, and even advertising these uses on websites or social media can trigger FDA penalties if it implies an unsupported claim. Home-brewed PRP is strongly discouraged because collection tubes are not meant for reinjection and may carry uncontrolled endotoxin or other contaminants. Exosomes are described as drugs by the FDA, with no FDA-approved human-derived products, while plant-based exosomes remain unproven in terms of equivalent therapeutic effect. Stem cell treatments are similarly complex: the processing methods typically involve manipulation that makes them fall outside minimal-manipulation status, meaning they are not FDA-cleared or approved. The speaker concludes that although these therapies are promising, evidence is limited, study quality is often weak, and larger controlled studies are needed to establish safe, effective protocols.
View moreConclusions
- PRP can be a useful and profitable treatment, but only when it is produced with an FDA-cleared device and used within the limits of its regulatory status.
- Using PRP for hair and skin is off-label, so clinicians must be careful because liability shifts from the manufacturer to the provider.
- Clinicians should avoid home-brewed PRP and non-cleared collection tubes because they are unpredictable, potentially unsafe, and not legally compliant.
- PRP should remain minimally manipulated and used immediately in the same patient; adding substances or altering the product can move it out of the cleared category.
- Exosomes derived from humans are currently treated by the FDA as drugs, with no FDA-approved human exosome products available for routine use.
- Plant-based exosomes may be promoted as a safer alternative, but their therapeutic equivalence to human-derived products remains unproven.
- Stem cell-based hair treatments are biologically promising but still rely on limited, weakly controlled evidence and are not close to standard practice.
- More rigorous, larger studies are needed to determine the best PRP concentration, preparation, injection technique, and treatment interval.
- Too-frequent PRP treatments may worsen hair loss, suggesting that more is not always better.
- Current stem cell and exosome commercialization for hair restoration remains legally and scientifically premature, so use should be approached with caution.
- Fang WH, Vangsness CT Jr. Food and Drug Administration's Position on Commonly Injected Biologic Materials in Orthopaedic Surgery. Am J Sports Med. 2021 Oct;49(12):3414-3421. doi: 10.1177/0363546521990900. Epub 2021 Mar 26. PMID: 33769895.#10.1177/0363546521990900
- Anderi R et al. Cellular Therapy with Human Autologous Adipose-Derived Adult Cells of Stromal Vascular Fraction. Stem Cell Research & Therapy. 2018;9:141.#10.1186/s13287-018-0889-y
- Jones, Togashi, and Thomas Vangness Jr. on the economics and regulation of PRP in orthopedic biologics.